HomeREGULATORY
REGULATORY

Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
(Mar.6.2018)

The overhaul of qualification criteria for the so-called price maintenance premium (PMP) in the FY2018 drug price revision led to mixed results for big-name medicines, with Januvia (sitagliptin) winning its first PMP, while Xarelto (rivaroxaban) and Humira (adalimumab) will be deprived of eligibility for what is seen as an all-important incentive for innovation by research-driven drug makers ...
(LOG IN FOR FULL STORY)

News Calendar